Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer's Disease Nasdaq:SAVA
Support a New Drug Application Filing for Simufilam in Alzheimer’s disease - - Agreement Reached to Use ADAS-Cog as Co-Primary Efficacy Endpoint - - Pivotal Phase 3 Program Remains On-track to be Initiated 2 nd Half 2021 - AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company developing product candidates for Alzheimer’s disease, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for simufilam, its lead drug candidate for the treatment of Alzheimer’s ...